Show simple item record

dc.contributor.author Gletsu-Miller, Nana
dc.contributor.author Lin, Edward
dc.contributor.author Davis, S. Scott
dc.contributor.author Srinivasan, Jahnavi
dc.contributor.author Sweeney, John F.
dc.contributor.author Ziegler, Thomas R.
dc.contributor.author Phillips, Lawrence
dc.date.accessioned 2019-11-18T18:53:48Z
dc.date.available 2019-11-18T18:53:48Z
dc.date.issued 2009-06
dc.identifier.citation Lin E., Davis, S.S., Srinivasan, J., Sweeney, J.F., Ziegler, T.R., Phillips, L.S., Gletsu-Miller, N. Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass. American Surgeon 75(6):498-502, 2009 en
dc.identifier.uri http://hdl.handle.net/2022/24717
dc.description.abstract Resolution of Type-2 diabetes mellitus (DM) after weight loss surgery is well documented, but the mechanism is elusive. We evaluated the glucose‐insulin metabolism of patients undergoing a Roux-en-Y gastric bypass (RYGB) using the intravenous glucose tolerance test (IVGTT) and compared it with patients who underwent laparoscopic adjustable gastric band (AB) placement. Thirty-one female patients (age range, 20 to 50 years; body mass index, 47.2 kg/m2) underwent RYGB. Nine female patients underwent AB placement and served as control subjects. All patients underwent IVGTT at baseline and 1 month and 6 months after surgery. Thirteen patients undergoing RYGB and one patient undergoing AB exhibited impaired glucose tolerance or DM defined by the American Diabetes Association. By 6 months post surgery, diabetes was resolved in all but one patient undergoing RYGB but not in the patient undergoing AB. Patients with diabetes undergoing RYGB demonstrated increased insulin secretion and β-cell responsiveness 1 month after surgery and continued this trend up to 6 months, whereas none of the patients undergoing AB had changes in β-cell function. Both patients undergoing RYGB and those undergoing AB demonstrated significant weight loss (34.6 and 35.0 kg/m2, respectively) and improved insulin sensitivity at 6 months. RYGB ameliorates DM resolution in two phases: 1) early augmentation of beta cell function at 1 month; and 2) attenuation of peripheral insulin resistance at 6 months. Patients undergoing AB only exhibited reduction in peripheral insulin resistance at 6 months but no changes in insulin secretion. en
dc.language.iso en en
dc.publisher American Surgeon en
dc.relation.isversionof https://www.ingentaconnect.com/contentone/sesc/tas/2009/00000075/00000006/art00008 en
dc.title Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass en
dc.type Article en


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search IUScholarWorks


Advanced Search

Browse

My Account

Statistics